Saturday, October 3, 2026

EUR/USD Bearish Momentum: 0.81% Down In The Last 5 Sessions

EUR/USD Bearish Momentum: 0.81% Down In The Last 5 Sessions

(VIANEWS) - EUR/USD (EURUSD) has been up by 0.81% for the last 5 sessions. At 22:07 EST on Wednesday, 12 June, EUR/USD (EURUSD) is $1.08.

EUR/USD's yearly highs and lows, it's 3.426% up from its 52-week low and 4.15% down from its 52-week high.

Volatility

EUR/USD's last week, last month's, and last quarter's current intraday variation average was a negative 0.19%, a positive 0.04%, and a positive 0.26%, respectively.

EUR/USD's highest amplitude of average volatility was 0.40% (last week), 0.26% (last month), and 0.26% (last quarter), respectively.

Previous days news about EUR/USD (EURUSD)

  • Eur/usd price analysis: not out of the woods yet, 100/200-day smas breakdown in play. According to FXStreet on Tuesday, 11 June, "This, in turn, favors bearish traders and validates the near-term negative outlook for the EUR/USD pair.", "The EUR/USD pair edges higher during the Asian session on Tuesday and currently trades around the 1.0765-1.0770 area, albeit lacks strong follow-through buying. "
  • Eur/usd price analysis: bears await US CPI and fed decision before placing fresh bets. According to FXStreet on Wednesday, 12 June, "Furthermore, oscillators on the daily chart are holding in the negative territory, suggesting that the path of least resistance for the EUR/USD pair is to the downside. ", "The EUR/USD pair oscillates in a narrow range during the Asian session on Wednesday and consolidates its losses registered over the past three days, to the 1.0720 area, or the lowest level since early May touched the previous day. "

More news about EUR/USD (EURUSD).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com